ReviewInfectious disorders drug targets2009
Benefits of structural genomics for drug discovery research.
Review in Infectious disorders drug targets, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- LEGO®-inspired electrically-actuated microfluidics for on-chip protein crystallization andLab on a chip · 2026Article
- Scalable fabrication of an array-type fixed-target device for automated room temperature X-ray protein crystallography.Scientific reports · 2025Article
- Nontraditional Roles of Magnesium Ions in Modulating Sav2152: Insight from a Haloacid Dehalogenase-like Superfamily Phosphatase fromInternational journal of molecular sciences · 2024Article
- Polymer-based microfluidic device for on-chip counter-diffusive crystallization andLab on a chip · 2023Article
- Molstack: A platform for interactive presentations of electron density and cryo-EM maps and their interpretations.Protein science : a publication of the Protein Society · 2020Article
- High precision protein functional site detection using 3D convolutional neural networks.Bioinformatics (Oxford, England) · 2019Article
- Survey of Predictors of Propensity for Protein Production and Crystallization with Application to Predict Resolution of Crystal Structures.Current protein & peptide science · 2018Article
- 3D deep convolutional neural networks for amino acid environment similarity analysis.BMC bioinformatics · 2017Article
- A public database of macromolecular diffraction experiments.Acta crystallographica. Section D, Structural biology · 2016Article
- Progress in protein crystallography.Protein and peptide letters · 2016Article
- X-ray crystallography over the past decade for novel drug discovery - where are we heading next?Expert opinion on drug discovery · 2015Review
- The future of crystallography in drug discovery.Expert opinion on drug discovery · 2014Review
- The quality and validation of structures from structural genomics.Methods in molecular biology (Clifton, N.J.) · 2014Article
- The role of protein structural analysis in the next generation sequencing era.Topics in current chemistry · 2014Review
- From laptop to benchtop to bedside: structure-based drug design on protein targets.Current pharmaceutical design · 2012Review
- The flow synthesis of heterocycles for natural product and medicinal chemistry applications.Molecular diversity · 2011Article
- X-ray crystallography: Assessment and validation of protein-small molecule complexes for drug discovery.Expert opinion on drug discovery · 2011Article
- High-throughput structural biology of metabolic enzymes and its impact on human diseases.Journal of inherited metabolic disease · 2011Review
- Unmet challenges of structural genomics.Current opinion in structural biology · 2010Review
- To automate or not to automate: this is the question.Journal of structural and functional genomics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
While three dimensional structures have long been used to search for new drug targets, only a fraction of new drugs coming to the market has been developed with the use of a structure-based drug discovery approach. However, the recent years have brought not only an avalanche of new macromolecular structures, but also significant advances in the protein structure determination methodology only now making their way into structure-based drug discovery. In this paper, we review recent developments resulting from the Structural Genomics (SG) programs, focusing on the methods and results most likely to improve our understanding of the molecular foundation of human diseases. SG programs have been around for almost a decade, and in that time, have contributed a significant part of the structural coverage of both the genomes of pathogens causing infectious diseases and structurally uncharacterized biological processes in general. Perhaps most importantly, SG programs have developed new methodology at all steps of the structure determination process, not only to determine new structures highly efficiently, but also to screen protein/ligand interactions. We describe the methodologies, experience and technologies developed by SG, which range from improvements to cloning protocols to improved procedures for crystallographic structure solution that may be applied in "traditional" structural biology laboratories particularly those performing drug discovery. We also discuss the conditions that must be met to convert the present high-throughput structure determination pipeline into a high-output structure-based drug discovery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.